Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus.
A 12-week double-blind placebo-controlled trial to study the effects of metformin on lipoprotein concentration and composition was performed in forty patients with NIDDM and hyperlipoproteinemia. A significant decrease occurred in VLDL-apo B and all lipid components of VLDL, indicating a decreased number of circulating VLDL, while LDL-apo B was unchanged. Moreover in VLDL the relative TG content increased, the cholesterol content decreased, while in LDL the TG content decreased and the cholesterol content increased, indicating a change in the particle distribution over the spectrum VLDL-IDL-LDL. The initially enhanced TG-content in HDL was reduced. While a reduction in VLDL is observed with all methods improving glucose control the observed compositional changes in VLDL and LDL have not been described before and may be a specific effect of metformin.